Re: Excess Risk of Primary Liver Cancer in Patients With Diabetes Mellitus

regard to the incidence and severity of mucositis. We believe that we did not observe an individual or chance response to intravenous immunoglobulin. With regard to the interference of oral mucositis with the patient’s nutrition and quality of life and to the potential risk of systemic infection due to disrupted barriers, we believe that intravenous immunoglobulin might be effective in prophylaxis of this chemotherapyand radiotherapyinduced toxicity.